Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coral calcium claims

This article was originally published in The Tan Sheet

Executive Summary

FDA has accepted petition for 26 coral calcium health claims for evaluation, petitioner Marine Bio announces March 4. The Japanese coral calcium firm notes FDA soon will post the claims for a 60-day public comment period. Washington, D.C.-based law firm Emord & Associates filed the claims for Marine Bio in October (1"The Tan Sheet" Oct. 13, 2003, p. 6). Claims sought include "may reduce risk of certain cancers." The FTC has successfully sued coral calcium marketers over false claims, enjoining them from misleading consumers (2"The Tan Sheet" Jan. 26, 2004 p. 10)...

You may also be interested in...



FTC Coral Calcium Settlement Includes Recall Of Falsely Labeled Products

Supplement promoter Robert Barefoot and his companies Deonna Enterprises and Karbo Enterprises have agreed to recall all coral calcium products with packaging, package inserts and labeling that carry unsupported disease claims under a stipulated settlement with the Federal Trade Commission

Coral Calcium Producer Seeks FDA Approval Of Disease Prevention Claims

Coral calcium producer Marine Bio USA is requesting FDA approval of health claims linking calcium with a reduced risk of several diseases including cancers, hypertension and menstrual disorders

2022 Korean VC Financings Led By Mid-Stage Bioventures

Amid a generally harsh environment, venture capital investors in South Korea appeared to take a more selective approach in 2022, with more established and financially stable domestic bioventures the biggest beneficiaries.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS096553

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel